Hoth therapeutics expands artificial intelligence initiative, selects nvidia ai enterprise platform

Under the new entitlement agreement, hoth therapeutics secures annual nvidia ai enterprise essentials licenses to support its gpu-powered infrastructure, enabling advanced machine learning and neural network modeling capabilities for pharmaceutical research new york , oct. 8, 2025 /prnewswire/ -- hoth therapeutics, inc. (nasdaq: hoth), a clinical-stage biopharmaceutical company focused on developing innovative therapies for dermatological, oncological disorders, today announced it has expanded its artificial intelligence (ai) initiative through a new nvidia ai enterprise subscription license to accelerate data-driven drug development, preclinical modeling, and predictive analytics. under the new entitlement and renewal agreement, hoth therapeutics has secured annual nvidia ai enterprise essentials licenses to support its gpu-powered infrastructure, enabling advanced machine learning and neural network modeling capabilities for pharmaceutical research.
NVDA Ratings Summary
NVDA Quant Ranking